IDEXX(US:IDXX) ZACKS·2026-02-02 13:41分组1 - Idexx Laboratories reported quarterly earnings of $3.08 per share, exceeding the Zacks Consensus Estimate of $2.93 per share, and showing an increase from $2.62 per share a year ago, resulting in an earnings surprise of +5.17% [1] - The company achieved revenues of $1.09 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.86%, and up from $954.29 million in the previous year [2] - Idexx has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] 分组2 - The stock has underperformed the market, losing about 0.9% since the beginning of the year, while the S&P 500 has gained 1.4% [3] - The current consensus EPS estimate for the upcoming quarter is $3.43 on revenues of $1.1 billion, and for the current fiscal year, it is $14.45 on revenues of $4.66 billion [7] - The Medical - Instruments industry, to which Idexx belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]